Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

An ideal Mounjaro diet plan should focus on nutrient-dense foods, such as fruits, vegetables, whole grains, lean proteins, ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

A Chinese start-up’s new artificial intelligence program took the top spot in Apple’s app store, threatening U.S. dominance ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...